非编码RNA作为癌症诊断和预后的临床生物标志物
Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis.
作者信息
Mishra Prasun J
机构信息
US Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Laboratory of Cancer Biology and Genetics, Bethesda, MD 20892, USA.
出版信息
Expert Rev Mol Diagn. 2014 Nov;14(8):917-9. doi: 10.1586/14737159.2014.971761.
Abstract
Developing more precise diagnostics approaches to predict cancer progression and prognosis is the key to precision medicine. Overwhelming evidence now suggests that small non-coding RNAs such as miRNAs can be useful tools as biomarkers for molecular diagnostics. miRNAs can serve as biomarkers in a variety of diseases, such as neurological disorders, cardiovascular disease, Type II diabetes, cancer and so on. miRNAs can not only be utilized for monitoring treatment but also for patient stratification and hence are promising predictive biomarkers in cancer progression and prognosis, as well as in predicting drug response. This article focuses on some of the recent findings in the field of miRNA biomarkers and discusses its implications for cancer diagnostics and precision medicine.
摘要
开发更精确的诊断方法以预测癌症进展和预后是精准医学的关键。现在有压倒性的证据表明，诸如miRNA等小非编码RNA可作为分子诊断生物标志物的有用工具。miRNA可作为多种疾病的生物标志物，如神经疾病、心血管疾病、II型糖尿病、癌症等。miRNA不仅可用于监测治疗，还可用于患者分层，因此在癌症进展和预后以及预测药物反应方面是很有前景的预测性生物标志物。本文重点介绍了miRNA生物标志物领域的一些最新发现，并讨论了其对癌症诊断和精准医学的意义。
相似文献
1
Non-coding RNAs as clinical biomarkers for cancer diagnosis and prognosis.非编码RNA作为癌症诊断和预后的临床生物标志物
Expert Rev Mol Diagn. 2014 Nov;14(8):917-9. doi: 10.1586/14737159.2014.971761.
2
MicroRNAs as promising biomarkers in cancer diagnostics.微小 RNA 作为癌症诊断有前景的生物标志物。
Biomark Res. 2014 Oct 22;2:19. doi: 10.1186/2050-7771-2-19. eCollection 2014.
3
MicroRNA as Biomarkers and Diagnostics.微小RNA作为生物标志物与诊断手段
J Cell Physiol. 2016 Jan;231(1):25-30. doi: 10.1002/jcp.25056.
4
Exosomal non-coding RNAs: a promising cancer biomarker.外泌体非编码RNA：一种有前景的癌症生物标志物。
Clin Chem Lab Med. 2016 Dec 1;54(12):1871-1879. doi: 10.1515/cclm-2016-0029.
5
MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine.微小RNA多态性：药物基因组学、分子流行病学及个体化医学的未来
Pharmacogenomics. 2009 Mar;10(3):399-416. doi: 10.2217/14622416.10.3.399.
6
Exosomal microRNAs and other non-coding RNAs as colorectal cancer biomarkers: a review.外泌体 microRNAs 和其他非编码 RNA 作为结直肠癌生物标志物：综述。
Mutagenesis. 2020 Jul 11;35(3):243-260. doi: 10.1093/mutage/gez038.
7
Non-coding RNAs Enabling Prognostic Stratification and Prediction of Therapeutic Response in Colorectal Cancer Patients.非编码RNA实现结直肠癌患者的预后分层及治疗反应预测
Adv Exp Med Biol. 2016;937:183-204. doi: 10.1007/978-3-319-42059-2_10.
8
Tumor-derived exosomal non-coding RNAs as diagnostic biomarkers in cancer.肿瘤来源的外泌体非编码 RNA 作为癌症的诊断生物标志物。
Cell Mol Life Sci. 2022 Oct 29;79(11):572. doi: 10.1007/s00018-022-04552-3.
9
The clinical relevance of circulating, exosomal miRNAs as biomarkers for cancer.循环外泌体微小RNA作为癌症生物标志物的临床相关性。
Expert Rev Mol Diagn. 2015;15(9):1159-69. doi: 10.1586/14737159.2015.1069183. Epub 2015 Jul 22.
10
Circulating non-coding RNAs as a tool for liquid biopsy in solid tumors.循环非编码RNA作为实体瘤液体活检的工具
Epigenomics. 2025 Apr;17(5):335-358. doi: 10.1080/17501911.2025.2467021. Epub 2025 Mar 5.
引用本文的文献
1
A three-plasma miRNA panel predicts the risk of colorectal cancer: a community-based nested case‒control study.三血浆 miRNA 标志物panel 预测结直肠癌风险：基于社区的巢式病例对照研究。
Sci Rep. 2023 Mar 14;13(1):4196. doi: 10.1038/s41598-023-31449-3.
2
Dysregulation of Long Non-coding RNAs and mRNAs in Plasma of Clear Cell Renal Cell Carcinoma Patients Using Microarray and Bioinformatic Analysis.利用微阵列和生物信息学分析研究透明细胞肾细胞癌患者血浆中长链非编码RNA和mRNA的失调情况
Front Oncol. 2020 Nov 27;10:559730. doi: 10.3389/fonc.2020.559730. eCollection 2020.
3
Circulating plasma microRNAs in colorectal neoplasia: A pilot study in assessing response to therapy.结直肠肿瘤中循环血浆微小RNA：评估治疗反应的一项初步研究
Transl Oncol. 2021 Jan;14(1):100962. doi: 10.1016/j.tranon.2020.100962. Epub 2020 Dec 4.
4
Differential MicroRNA-Signatures in Thyroid Cancer Subtypes.甲状腺癌亚型中的差异微小RNA特征
J Oncol. 2020 Jun 3;2020:2052396. doi: 10.1155/2020/2052396. eCollection 2020.
5
Genome-wide long non-coding RNAs identified a panel of novel plasma biomarkers for gastric cancer diagnosis.全基因组长链非编码 RNA 鉴定了一组用于胃癌诊断的新型血浆生物标志物。
Gastric Cancer. 2019 Jul;22(4):731-741. doi: 10.1007/s10120-018-00915-7. Epub 2019 Jan 2.
6
Cell Type-Selective Expression of Circular RNAs in Human Pancreatic Islets.人胰岛中环状RNA的细胞类型选择性表达
Noncoding RNA. 2018 Nov 27;4(4):38. doi: 10.3390/ncrna4040038.
7
Pattern recognition for predictive, preventive, and personalized medicine in cancer.癌症预测、预防和个性化医疗中的模式识别
EPMA J. 2017 Mar 9;8(1):51-60. doi: 10.1007/s13167-017-0083-9. eCollection 2017 Mar.
8
Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis.基于血液的微小RNA作为结直肠癌诊断生物标志物的系统评价与荟萃分析
Br J Cancer. 2017 Mar 14;116(6):762-774. doi: 10.1038/bjc.2017.12. Epub 2017 Feb 2.
9
A Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma MicroRNA: Improving Specificity and Sensitivity.一种使用血浆微小RNA诊断结直肠肿瘤的高度预测模型：提高特异性和敏感性。
Ann Surg. 2016 Oct;264(4):575-84. doi: 10.1097/SLA.0000000000001873.
10
Biobanking of Exosomes in the Era of Precision Medicine: Are We There Yet?精准医学时代的外泌体生物样本库：我们做到了吗？
Int J Mol Sci. 2015 Dec 24;17(1):13. doi: 10.3390/ijms17010013.
本文引用的文献
1
microRNAs in the tumor microenvironment: solving the riddle for a better diagnostics.肿瘤微环境中的 microRNAs：为更好的诊断解开谜团。
Expert Rev Mol Diagn. 2014 Jun;14(5):565-74. doi: 10.1586/14737159.2014.922879.
2
Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma.血浆 microRNA 是经典霍奇金淋巴瘤的疾病反应生物标志物。
Clin Cancer Res. 2014 Jan 1;20(1):253-64. doi: 10.1158/1078-0432.CCR-13-1024. Epub 2013 Nov 12.
3
Comparisons of microRNA patterns in plasma before and after tumor removal reveal new biomarkers of lung squamous cell carcinoma.对比肿瘤切除前后血浆中的 miRNA 图谱，揭示肺鳞癌的新型生物标志物。
PLoS One. 2013 Oct 9;8(10):e78649. doi: 10.1371/journal.pone.0078649. eCollection 2013.
4
MicroRNA and protein profiling of brain metastasis competent cell-derived exosomes.脑转移能力细胞衍生的外泌体的 miRNA 和蛋白质谱分析。
PLoS One. 2013 Sep 16;8(9):e73790. doi: 10.1371/journal.pone.0073790. eCollection 2013.
5
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.循环 microRNA 谱分析确定了一组转移性前列腺癌患者，这些患者有癌症相关缺氧的证据。
PLoS One. 2013 Jul 30;8(7):e69239. doi: 10.1371/journal.pone.0069239. Print 2013.
6
A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer.一种在胰腺癌中进行高灵敏度微小RNA原位杂交和免疫组织化学分析的方法。
Methods Mol Biol. 2013;980:43-59. doi: 10.1007/978-1-62703-287-2_4.
7
Elevated levels of circulating microRNA-200 family members correlate with serous epithelial ovarian cancer.循环 microRNA-200 家族成员水平升高与浆液性上皮性卵巢癌相关。
BMC Cancer. 2012 Dec 28;12:627. doi: 10.1186/1471-2407-12-627.
8
Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.鉴定循环 microRNAs 作为多发性骨髓瘤的诊断生物标志物。
Br J Cancer. 2012 Dec 4;107(12):1987-96. doi: 10.1038/bjc.2012.525. Epub 2012 Nov 20.
9
The miRNA-drug resistance connection: a new era of personalized medicine using noncoding RNA begins.微小RNA与耐药性的关联：一个利用非编码RNA的个性化医疗新时代开启。
Pharmacogenomics. 2012 Sep;13(12):1321-4. doi: 10.2217/pgs.12.121.
10
Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer.循环 miR-200c 作为胃癌的诊断和预后生物标志物。
J Transl Med. 2012 Sep 6;10:186. doi: 10.1186/1479-5876-10-186.
Zotero 插件